top of page

Detailed Post 

Compendial reference of USP or NF excipients

Updated: Apr 3, 2023


 

Compendial reference of USP or NF excipients

This information is providing background on the approach which was introduced for referencing excipients, which are in compliance with an USP or NF monograph.

It is recommended to provide in IND/IMPDs and MAA/NDA/BLA dossiers for excipients, which are listed in USP and/or NF the mreferencinguspornfexcipientsinanapplicationore general compendial reference “USP/NF”, if these excipients are tested in compliance with the respective USP and/or NF monograph

Previous standard was to differentiate between excipients listed either in USP or NF to guide the reviewers, in which parts of the USP/NF publication a specific excipient could be found. But recent experience with agencies led to streamline the approach.




Comments


logo apsyos

Our Address

Talk To our Experts

Email Us

We are located near Basel

Thanks for subscribing!

Apsyos

As Health is the main priority in our lives, it is important that patients get the most appropriate and safe treatments in the fastest and most reliable way without compromising of its quality.

About

​Apsyos offers small and medium pharmaceutical and biologic manufacturers the freedom to focus their internal capacities towards Science and Clinical Concerns by alleviating technical regulatory aspects.

We are operating from London and Basel

Map

©2021 par Apsyos. Créé avec Wix.com.

About Us   Services   Privacy

J2 RA CMC Services Ltd, 128 City Road EC1V 2NX, London, United Kingdom

Registered Company Nr: 16260386

bottom of page